Cytochroma to present at the Cowen and Company 32nd Annual Healthcare Conference

MARKHAM, ON, Feb. 29, 2012 /CNW/ - Cytochroma today announced that Dr. Charles W. Bishop, Cytochroma's President and Chief Executive Officer, will present a corporate overview at the Cowen and Company 32nd Annual Health Care Conference.  This presentation is scheduled at 2:00 PM ET on Monday, March 5, 2012 at the Boston Marriott Copley Place.

About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD).  The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD.  Cytochroma also has a portfolio CYP24 and phosphate-uptake inhibitors in early stage development.

SOURCE Cytochroma

For further information:

Please visit www.cytochroma.com.

Cytochroma Investors:
Gordon Ngan
Executive Director, Corporate Development
Tel: +1 (905) 479-5306 ext. 333
gngan@cytochroma.com

Cytochroma Media:
Robert Stanislaro (FTI Consulting)
Tel: +1 (212) 850-5657
robert.stanislaro@fticonsulting.com

Organization Profile

Cytochroma

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890